素-聚合物结合物作为脂质体生物活性输送系统的功能性涂层
Trang Le1, Tien-Dung Nguyen-Dinh2, Anh-Minh Nguyen-Huu3
1Institute of Applied Materials Science, Vietnam Academy of Science and Technology, Biomaterials & Bioengineering, 01B TL29, Thanh Loc Ward, District 12, 084, Ho Chi Minh, VIET NAM.
ChemMedChem
|May 19, 2025
概括
这项研究开发的聚合物涂层脂质体使用奇托-聚乙烯糖醇-叶酸 (CTS-PEG-FA) 增强药物输送. 这些功能化的脂质体显示出细胞吸收的改善和强大的抗癌作用,为药物递送系统提供了一个有希望的平台.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 药物输送系统 药物输送系统
背景情况:
- 传统的脂质体在药物输送方面面临局限性,原因是清除速度快,向不佳.
- 聚合物涂层脂质体提供了增强的生物相容性和有针对性的传递能力.
- 奇托-聚乙烯甘醇-叶酸 (CTS-PEG-FA) 结合物为功能化脂质体提供了一种新的方法.
研究的目的:
- 为了合成和描述用于脂质体涂层的CTS-PEG-FA合物.
- 准备和分析用于药物输送应用的CTS-PEG-FA涂层脂质体.
- 评估开发系统的药物载荷能力,释放动力学,细胞吸收和细胞毒性.
主要方法:
- 合成和光谱对CTS-PEG-FA结合物的表征.
- 使用薄膜水化方法制备脂质体.
- 脂质体特征 (颗粒大小,泽塔潜力,形态) 和药物递送性能 (加载,释放,吸收,细胞毒性) 的分析.
主要成果:
- 成功合成和表征了CTS-PEG-FA合物.
- 用CTS-PEG-FA涂层的脂质体表现出有利的粒子大小,泽塔潜力和形态.
- 该系统证明了细胞吸收的增强和对癌细胞的显著细胞毒性作用,使用氨酸作为模型药物.
结论:
- 用CTS-PEG-FA涂层的脂质体代表了一种高效和多功能平台,用于生物活性化合物的输送.
- 开发的功能化脂质体显示出在癌症治疗中改善治疗性能的潜力.
- 这种方法通过克服传统脂质体的局限性来增强药物递送系统.
更多相关视频
相关概念视频
01:16Bioavailability Enhancement: Drug Solubility Enhancement
499
Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
499
01:27Bioavailability Enhancement: Drug Permeability Enhancement
352
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
352
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
01:24Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
01:11Oral Drug Delivery Systems: Delayed-Release Systems
222
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
222